Key highlights
- Vitura Health shares traded at $0.017 at 11:04 AM AEDT on 19 November 2026, down 10.53%, while the S&P/ASX 200 was up 0.83% around midday.
- First quarter FY27 Revenue rose $1.7 million, or 4.8%, and EBITDA rose $1.01 million on the prior corresponding period.
- The company finalised a Three Horizon Plan, with its first phase focused on the 12 to 18 months to come.
Shares in Vitura Health Limited (ASX:VIT) were trading at $0.017 during the session on 19 November 2026, down 10.53% at 11:04 AM AEDT, while the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. Vitura describes itself as a digital health Business with clinical services and platforms for prescribing and ordering. In its Q1 FY2027 operational update dated 13 October 2026, the company reported first-quarter revenue, EBITDA and operating expenditure ahead of expectations, and set out its plan to return the business to profitability.
First Quarter Results
Revenue rose $1.7 million, or 4.8%, on the prior corresponding period, while EBITDA rose $1.01 million, or 197.5%. Operational expenditure fell $685,000, or 9.5%. The company said the figures were ahead of expectations across revenue, EBITDA and operating expenditure. Its Candor clinical services business saw growth in consultations, medical cannabis dispensing volumes were up 19% on the fourth quarter of FY2026, and the Canview ordering platform benefited from a pharmacy promotion.
Three Horizon Plan and Doctors on Demand
The company finalised its Three Horizon Plan, endorsed by the board, with Horizon One covering a 12 to 18 month period. Its priorities include improving patient access through distribution and fulfilment, enhancing platforms and processes, embedding a clinical governance framework, reviewing contracting and Margin stability, and maintaining expense discipline. Doctors on Demand revenue exceeded expectations, although Bupa patient consultations are winding down, and the company is aligning its operating infrastructure to anticipated volumes.
Sector Context
Digital health businesses in Australia operate across telehealth consultations, prescribing platforms and pharmacy supply, and the sector is sensitive to changes in regulation, reimbursement and the terms of private health insurer arrangements. Medical cannabis prescribing is subject to specific regulatory frameworks that can change over time.
Risks Investors Are Watching
The Bupa-related consultation volumes at Doctors on Demand are winding down, which will affect the revenue base. The company says it is still working to return to profitability, and the plan depends on distribution, contracting and margin work still underway. Regulatory and contracting changes in healthcare services may also affect the outlook.
What to Watch Ahead
Investors will be watching the Annual General Meeting on 27 November 2026, where the company has said it will share more detail on the Three Horizon Plan, along with progress on margins and expenses and the level of consultation volumes at Doctors on Demand.
About the Company
Vitura Health Limited is an ASX-listed digital health company whose businesses include Candor, a business-to-consumer clinical services provider, Canview, a business-to-business ordering and prescribing platform, and Doctors on Demand. The company also has emerging markets activity including nicotine vaping products and Supply arrangements that support Emyria's expansion into Sydney.
Session Context
The shares were trading at $0.017 during the session on 19 November 2026, down 10.53% at 11:04 AM AEDT. These are intraday figures rather than a closing price, so the move reflects trade in progress at that time. Over the same period the S&P/ASX 200 was up 0.83% at 8,748.30 around midday. In the previous session on 18 November, the Dow Jones closed down 1.32% and the Nasdaq closed down 0.02%. Trading conditions can change quickly during a session, so later moves may differ from the figures shown here. The benchmark figures quoted above are the level and percentage change reported at midday on the same day.
Closing Note
Vitura shares fell in mid-morning trade on 19 November 2026. The annual general meeting and the next quarterly figures will show whether the first-quarter improvement carries forward.






Please wait processing your request...